

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/226261 A1

(51) International Patent Classification:

A61K 31/397 (2006.01) A61K 31/53 (2006.01)
A61K 31/4155 (2006.01)

(21) International Application Number:

PCT/US2022/025875

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/178,922 23 April 2021 (23.04.2021) US

(71) Applicant: **KINNATE BIOPHARMA INC.** [US/US];
12830 El Camino Real, Suite 150, San Diego, California
92130 (US).

(72) Inventors: **FRANOVIC, Aleksandra**; 12830 El Camino
Real, Suite 150, San Diego, California 92130 (US).
MARTIN, Eric; 12830 El Camino Real, Suite 150, San
Diego, California 92130 (US). **MILLER, Nichol L. G.**;
12830 El Camino Real, Suite 150, San Diego, Califor-
nia 92130 (US). **MURPHY, Eric**; 12830 El Camino Real,
Suite 150, San Diego, California 92130 (US). **WILLIAMS,
Richard Thomas**; 12830 El Camino Real, Suite 150, San
Diego, California 92130 (US).

(74) Agent: **CLARK, David**; WILSON SONSINI GOODRICH
& ROSATI, 650 Page Mill Road, Palo Alto, California
94304 (US).


(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: TREATMENT OF CANCER WITH A RAF INHIBITOR



(57) Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.

[Continued on next page]

Published:

— with international search report (Art. 21(3))